TradingKey

关于 SpringWorks Therapeutics Inc 公司

SpringWorks Therapeutics, Inc. 是一家专注于严重罕见疾病和癌症的商业阶段生物制药公司。OGSIVEO（nirogacestat）是该公司经美国食品药品监督管理局 (FDA) 批准的疗法。OGSIVEO（nirogacestat）在美国获批用于治疗需要全身治疗的进展性纤维瘤成年患者。该公司还拥有多元化的靶向治疗产品线，涵盖实体瘤和血液癌症，项目范围从临床前开发到高级临床试验。其正在进行的开发包括用于治疗卵巢颗粒细胞瘤的 Nirogacestat、Nirogacestat 与 B 细胞成熟抗原 (BCMA) 靶向药物的联合使用、针对 NF1-PN 的 Mirdametinib 第 2b 期 ReNeu 试验和 Brimarafenib (BGB-3245)。该公司的早期产品线包括 SW-682，一种在研口服小分子 TEA 结构域 (TEAD) 抑制剂，针对 Hippo 突变型实体瘤进行了评估。

公司简介

公司代码SWTX

公司名称SpringWorks Therapeutics Inc

上市日期Sep 13, 2019

CEOMr. Saqib Islam, J.D.

员工数量368

证券类型Ordinary Share

年结日Sep 13

公司地址100 Washington Blvd

城市STAMFORD

上市交易所NASDAQ Global Select Consolidated

国家United States of America

邮编06902-9302

电话12038839490

网址https://www.springworkstx.com/

公司代码SWTX

上市日期Sep 13, 2019

CEOMr. Saqib Islam, J.D.

公司高管

名称

名称/职务

职务

持股

持股变动

Dr. Badreddin Edris, Ph.D.

Chief Operating Officer

102.78K

--

Mr. Daniel S. (Dan) Lynch

Independent Chairman of the Board

82.94K

--

Dr. James (Jim) Cassidy, M.D., Ph.D.

Chief Medical Officer

35.86K

+5.56%

Mr. Bhavesh Ashar

Chief Commercial Officer

19.30K

--

Mr. Carlos Alban

Independent Director

15.38K

--

Mr. Francis (Frank) Perier, Jr.

Chief Financial Officer

--

Mr. Herschel S. Weinstein, J.D.

General Counsel, Secretary

--

Mr. Alan Fuhrman, CPA

Independent Director

--

Mr. Daniel Pichl

Chief People Officer

--

-100.00%

Dr. Julie Hambleton, M.D.

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Dr. Badreddin Edris, Ph.D.

Chief Operating Officer

102.78K

--

Mr. Daniel S. (Dan) Lynch

Independent Chairman of the Board

82.94K

--

Dr. James (Jim) Cassidy, M.D., Ph.D.

Chief Medical Officer

35.86K

+5.56%

Mr. Bhavesh Ashar

Chief Commercial Officer

19.30K

--

Mr. Carlos Alban

Independent Director

15.38K

--

Mr. Francis (Frank) Perier, Jr.

Chief Financial Officer

--

收入明细

FY2025Q1

FY2024

FY2023

FY2023Q4

FY2022

FY2021

FY2020

暂无数据

地区USD

名称

营收

占比

United States

49.09M

0.00%

业务

地区

暂无数据

股东统计

更新时间: 5月20日周二

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

9.38%

BlackRock Institutional Trust Company, N.A.

7.00%

State Street Global Advisors (US)

3.87%

T. Rowe Price Associates, Inc.

3.33%

Woodline Partners LP

2.85%

Other

73.56%

持股股东

占比

The Vanguard Group, Inc.

9.38%

BlackRock Institutional Trust Company, N.A.

7.00%

State Street Global Advisors (US)

3.87%

T. Rowe Price Associates, Inc.

3.33%

Woodline Partners LP

2.85%

Other

73.56%

股东类型

持股股东

占比

Investment Advisor

35.29%

Investment Advisor/Hedge Fund

26.11%

Hedge Fund

16.63%

Research Firm

3.54%

Private Equity

1.26%

Individual Investor

1.22%

Family Office

1.13%

Venture Capital

1.05%

Pension Fund

0.87%

Other

12.89%

机构持股

更新时间: 7月1日周二

报告期

机构数

持股数

持股占比

持股变动

2025Q2

173

582.21K

0.77%

-8.67M

2025Q1

573

77.70M

103.24%

-22.69M

2024Q4

490

88.41M

118.04%

-11.55M

2024Q3

479

87.46M

117.75%

-11.59M

2024Q2

454

81.87M

110.52%

-15.83M

2024Q1

437

83.09M

112.25%

-11.87M

2023Q4

403

80.24M

109.81%

+3.34M

2023Q3

387

75.55M

121.85%

-8.83M

2023Q2

384

76.79M

123.93%

-3.97M

2023Q1

390

73.34M

118.42%

-7.19M

股东持股明细

名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

7.07M

9.38%

-75.64K

-1.06%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

5.27M

7%

-84.34K

-1.57%

Mar 31, 2025

State Street Global Advisors (US)

2.92M

3.87%

-84.64K

-2.82%

Mar 31, 2025

T. Rowe Price Associates, Inc.

2.51M

3.33%

-694.86K

-21.68%

Mar 31, 2025

Woodline Partners LP

2.14M

2.85%

+654.68K

+43.93%

Mar 31, 2025

Polar Capital LLP

1.75M

2.32%

+250.00K

+16.67%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.72M

2.28%

+45.24K

+2.71%

Mar 31, 2025

Pictet Asset Management Ltd.

1.67M

2.22%

-721.40K

-30.17%

Mar 31, 2025

D. E. Shaw & Co., L.P.

1.66M

2.21%

+1.28M

+329.03%

Mar 31, 2025

ArrowMark Colorado Holdings, LLC

1.46M

1.94%

-40.06K

-2.67%

Mar 31, 2025

持股ETF

更新时间: 7月6日周日

机构名称

占比

AltShares Event-Driven ETF

7.06%

AltShares Merger Arbitrage ETF

6.46%

First Trust Merger Arbitrage ETF

5.56%

iShares Genomics Immunology and Healthcare ETF

4.03%

ProShares Merger ETF

3.76%

First Trust Innovation Leaders ETF

1.45%

SPDR S&P Biotech ETF

1.41%

WisdomTree BioRevolution Fund

0.94%

Direxion Daily S&P Biotech Bull 3X Shares

0.76%

First Trust Small Cap Growth AlphaDEX Fund

0.5%

AltShares Event-Driven ETF

占比7.06%

AltShares Merger Arbitrage ETF

占比6.46%

First Trust Merger Arbitrage ETF

占比5.56%

iShares Genomics Immunology and Healthcare ETF

占比4.03%

ProShares Merger ETF

占比3.76%

First Trust Innovation Leaders ETF

占比1.45%

SPDR S&P Biotech ETF

占比1.41%

WisdomTree BioRevolution Fund

占比0.94%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.76%

First Trust Small Cap Growth AlphaDEX Fund

占比0.5%

分红派息

近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股

公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

SpringWorks Therapeutics Inc

46.990USD

SpringWorks Therapeutics Inc

46.990

概览

公司

财务